ECGSIM: an interactive tool for studying the genesis of QRST waveforms

Por van Oosterom, A, Oostendorp, T F
Publicado em 2004

High endothelial cell proliferation index and high microvessel density in vascular hotspots suggest an active angiogenic process in human colorectal adenocarcinomas. Angiogenesis G...

Por Vermeulen, P. B., Dirix, L. Y., Van Marck, E., Van Oosterom, A. T.
Publicado em 1996

A comparison of two culture techniques: an in vitro & an in vivo tumour colony-forming assay.

Por Slee, P. H., Willemze, R., van Oosterom, A. T., Lurvink, E., van den Berg, L.
Publicado em 1985

A phase II trial with rosiglitazone in liposarcoma patients

Por Debrock, G, Vanhentenrijk, V, Sciot, R, Debiec-Rychter, M, Oyen, R, Van Oosterom, A
Publicado em 2003

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Geni...

Por De Mulder, P. H., Oosterhof, G., Bouffioux, C., van Oosterom, A. T., Vermeylen, K., Sylvester, R.
Publicado em 1995

Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.

Por Hellemans, P, van Dam, P A, Geyskens, M, van Oosterom, A T, Buytaert, P, Van Marck, E
Publicado em 1995

Prognostic value of bcl-2 expression in invasive breast cancer.

Por Hellemans, P., van Dam, P. A., Weyler, J., van Oosterom, A. T., Buytaert, P., Van Marck, E.
Publicado em 1995

Variations in exposure to mitomycin C in an in vitro colony-forming assay.

Por Slee, P. H., de Bruijn, E. A., Leeflang, P., Kuppen, P. J., van den Berg, L., van Oosterom, A. T.
Publicado em 1986

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11

Por Wildiers, H, Guetens, G, De Boeck, G, Verbeken, E, Landuyt, B, Landuyt, W, de Bruijn, E A, van Oosterom, A T
Publicado em 2003

Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.

Por Dirix, L. Y., Vermeulen, P. B., Pawinski, A., Prové, A., Benoy, I., De Pooter, C., Martin, M., Van Oosterom, A. T.
Publicado em 1997

Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study.

Por Vermeulen, P. B., Verhoeven, D., Fierens, H., Hubens, G., Goovaerts, G., Van Marck, E., De Bruijn, E. A., Van Oosterom, A. T., Dirix, L. Y.
Publicado em 1995

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.

Por Bontenbal, M., Andersson, M., Wildiers, J., Cocconi, G., Jassem, J., Paridaens, R., Rotmensz, N., Sylvester, R., Mouridsen, H. T., Klijn, J. G., van Oosterom, A. T.
Publicado em 1998

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.

Por Pronk, L. C., Schrijvers, D., Schellens, J. H., de Bruijn, E. A., Planting, A. S., Locci-Tonelli, D., Groult, V., Verweij, J., van Oosterom, A. T.
Publicado em 1998

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study

Por Fokkema, E, Verweij, J, van Oosterom, A T, Uges, D R A, Spinelli, R, Valota, O, de Vries, E G E, Groen, H J M
Publicado em 2000

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Por Punt, C. J., Voest, E. E., Tueni, E., Van Oosterom, A. T., Backx, A., De Mulder, P. H., Hecquet, B., Lucas, C., Gerard, B., Bleiberg, H.
Publicado em 1997

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

Por Wachters, F M, Groen, H J M, Maring, J G, Gietema, J A, Porro, M, Dumez, H, de Vries, E G E, van Oosterom, A T
Publicado em 2004

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)

Por Fosså, S D, Paluchowska, B, Horwich, A, Kaiser, G, de Mulder, P H M, Koriakine, O, van Oosterom, A T, de Prijck, L, Collette, L, de Wit, R
Publicado em 2005

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

Por Huygh, G., Clement, Paul M. J., Dumez, H., Schöffski, P., Wildiers, H., Selleslach, J., Jimeno, J. M., Wever, I. De, Sciot, R., Duck, L., Van Oosterom, A. T.
Publicado em 2006

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

Por de Wit, R., Collette, L., Sylvester, R., de Mulder, P. H., Sleijfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Stoter, G.
Publicado em 1998

Pharmacokinetics and bioavailability of oral 5′-deoxy-5-fluorouridine in cancer patients

Por Van Der Heyden, S A M, Highley, M S, De Bruijn, E A, Tjaden, U R, Reeuwijk, H J E M, Van Slooten, H, Van Oosterom, A T, Maes, R A A
Publicado em 1999